DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain . ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.
See more here:
King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain
